Table 5.
N-glycans Peak # | Sucrose preference (r) | Immobility duration (r) | Line crossing (r) | Clinical score (r) |
---|---|---|---|---|
A | ||||
14 | −0.558** | 0.176 | 0.484* | |
15 | 0.303 | −0.896*** | −0.703*** | |
B | ||||
14 | 0.696** | 0.845*** | 0.497* | 0.159 |
15 | −0.389* | 0.096 | 0.032 | 0.920*** |
C | ||||
14 | 0.766*** | −0.580** | −0.141 | −0.168 |
15 | −0.210 | 0.026 | −0.163 | 0.439* |
D | ||||
14 | 0.993*** | 0.895** | 0.961*** | −0.867*** |
15 | −0.968*** | −0.673** | −0.797** | 0.988*** |
Each value represent Pearson’s correlation coefficients *** [r] = 0.7, strong correlation, ** [r] = 0.5–0.7, moderately to strong correlation, and * [r] = 0.3–0.5, weak to moderate correlation. BALB/c- exposed to chronic T. gondii], (A); BALB/c- exposed to acute T. gondii, (B); BALB/c- treated with 1-methyl tryptophan (1-MT) after exposure to acute T. gondii], (C); and severe combined immune deficiency (SCID)-exposed to acute T. gondii], (D). SD: standard deviation.